CSI Market
Sign In | Register

Vir Biotechnology Inc (VIR) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access VIR Annual Cash Flow →
The table below presents a historical view of Vir Biotechnology Inc's cash flow activity, supporting analysis of liquidity trends over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-45.62
Depreciation & amortization5.61
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation24.48
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants0.00
Change In Fair Value Of Contingent Consideration-
Preferred Stock Issued In Connection With Asset Acquisition-
Change In Estimated Fair Value Of Contingent Consideration-0.89
Initial Fair Value Of Derivative Liability-
Noncash Lease Expense1.34
Assets Fair Value Adjustment0.17
Gain Loss On Termination Of Lease-
Common Stock Issued In Connection With License Agreement-
Changes In Estimated Constraint On Profit Sharing Amount-
Increase Decrease In Payment Of Contingent Consideration In Excess Of Acquisition Date Fair Value-
Change In Estimated Constraint On Profit Sharing Amount-
Adjustment To Reconcile Net Income To Cash Provided By Used In Operating Activity Other Non Cash Items Net0.08
Impairment Long Lived Asset Held For Use And Disposal Gain Loss-
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.00
Increase (Decrease) in Accounts Payable8.08
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities-8.83
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-6.06
Other Working Capital-0.05
Other Noncash Income (Expense)0.00
Other net-0.72
Payments for (Proceeds from) Other Operating Activities14.04
Discontinued operations0.00
Net Cash flow from Operating Activities-9.06
Investing Activities
Capital Expenditures-0.42
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Proceeds From Sale Of Equipment-
Proceeds From Disposal Of An Equipment-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments-184.89
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-185.31
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock2.97
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net237.93
Finance Lease Principal Payments-
Proceeds From Repayment Of Promissory Notes-
Capital Expenditures Incurred But Not Yet Paid-
Issuance Costs For Convertible Preferred Stock Included In Accounts Payable And Accrued Liabilities-
Noncash Or Part Noncash Acquisition Value Of Assets Acquired-
Deferred Issuance Costs Incurred And Not Paid-
Advanced Proceeds From Convertible Preferred Stock Financing-
Payment Of Contingent Consideration-
Payments Related To Sale Lease Back Obligation-
Restricted Cash And Cash Equivalents At Carrying Value1.93
Restricted Cash And Cash Equivalents Noncurrent6.96
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents241.07
Proceeds From Issuance Of Common Stock In Connection With Collaboration-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities240.90
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-9.48
Total Cash Flow46.53
4 historic quarters locked

Sign in to unlock the full Vir Biotechnology Inc cash flow history.

Sign In Create Free Account

About Vir Biotechnology Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20260630)
  • Filed with the SEC: August 5, 2026
  • Source: vir-20260630.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001628280-26-053549

Figures are derived from filed reports and may be restated. Historical data is subject to revision.